Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mepyramine is a first-generation antihistamine used for the symptomatic treatment of allergy, hypersensitivity reactions, and pruritic skin disorders. Also known as pyrilamine or as its salt form pyrilamine maleate, it acts as a histamine H1 receptor inverse agonist. Mepyramine binds to the G protein-coupled form of the H1 receptor and promotes an inactive state that interferes with Gq/11-mediated signaling. This results in suppression of histaminic edema (swelling), flare (redness), and pruritus (itching). Due to its ability to rapidly cross the blood-brain barrier and act at subcortical levels in the CNS, it often causes drowsiness as a side effect. Mepyramine has been included in over-the-counter combination products for colds and menstrual symptoms but is considered unapproved for some uses in certain countries[1][2][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on mepyramine.